Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Peter Overbeck
No abstract text is available yet for this article.
May 2024: MMW Fortschritte der Medizin
#2
JOURNAL ARTICLE
Johan Björklund, Louise Pettersson, Björn Agvall
BACKGROUND: Heart failure (HF) has a high prevalence in an elderly population and leads to a substantial hospitalization and mortality. The objective of this study was to investigate factors that affect hospitalization and mortality in an elderly population. METHODS: A retrospective observational study was conducted of HF patients aged 76-95 years residing in Region Halland, Sweden. Between 2013 and 2019, a total of 3134 patients received a novel diagnosis of HF and were subsequently monitored for one year using data from a healthcare database...
April 26, 2024: BMC Cardiovascular Disorders
#3
REVIEW
A Coca, S P Whelton, M Camafort, J P López-López, E Yang
Elevated blood pressure (BP) is the largest contributor to the incident cardiovascular disease worldwide. Despite explicit guideline recommendations for the diagnosis and management of hypertension, a large proportion of patients remain undiagnosed, untreated, or treated but uncontrolled. Inadequate BP control is associated with many complex factors including patient preference, physician's inertia, health systems disparities, and poor adherence to prescribed antihypertensive drug treatment. The primary driver for reduced cardiovascular morbidity and mortality is lowering of BP ''per se'' and not class effects of specific pharmacotherapies...
April 22, 2024: European Journal of Internal Medicine
#4
JOURNAL ARTICLE
Juan Esteban de Villarreal-Soto, Juan Francisco Oteo-Domínguez, Daniel Martínez-López, Elsa Carolina Ríos-Rosado, Beatriz Vera-Puente, Jean Carlo Olivo-Soto, Fernando Arízaga-Arce, Pablo García-Pavía, Víctor Manuel Ospina Mosquera, Susana Villar García, Jessica García Suárez, Miguel Ángel Cavero, Carlos Esteban Martín-López, Alberto Forteza-Gil
OBJECTIVES: Extended septal myectomy and alcohol septal ablation are two invasive treatments for hypertrophic obstructive cardiomyopathy. We aim to compare which of these techniques achieves a higher reduction in gradients, improvement in NYHA class and reduction in medical treatment. METHODS: This is a single-center observational and retrospective analysis. This is a single-center observational and retrospective analysis. We have used multivariable regression analyses to assess the association of ablation/myectomy with different outcomes...
April 3, 2024: Interdiscip Cardiovasc Thorac Surg
#5
REVIEW
Sergio Henrique Rodolpho Ramalho, André Luiz Pereira de Albuquerque
PURPOSE OF REVIEW: Chronic obstructive pulmonary disease (COPD) is common in heart failure (HF), and it has a significant impact on the prognosis and quality of life of patients. Additionally, COPD is independently associated with lower adherence to first-line HF therapies. In this review, we outline the challenges of identifying and managing HF with preserved (HFpEF) and reduced (HFrEF) ejection fraction with coexisting COPD. RECENT FINDINGS: Spirometry is necessary for COPD diagnosis and prognosis but is underused in HF...
March 28, 2024: Current Heart Failure Reports
#6
JOURNAL ARTICLE
Lestak Jan, Fus Martin, Pitrova Sarka
BACKGROUND AND AIM: In a previous follow-up of glaucoma patients taking carteolol or latanoprost, we found a greater progression of visual field changes with the prostaglandin than the betablocker. In the present study we compared the impact of carteolol and latanoprost on peripapillary vessel density in newly diagnosed primary open-angle glaucoma (POAG) patients. METHODS: The study consisted of two groups of POAG patients. There were 46 patient eyes treated with carteolol (Carteol LP 2%) in the first group and 52 eyes treated with latanoprost (Xalatan 0...
March 21, 2024: Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
#7
JOURNAL ARTICLE
Samuela Carigi, Piero Gentile, Mauro Gori, Denitza Tinti, Luisa De Gennaro, Giuseppe Leonardi, Francesco Orso, Anna Rita Felici, Maria Rosaria Catalano, Marina Floresta, Vittoria Rizzello, Donata Lucci, Lucio Gonzini, Renata De Maria, Marco Marini
BACKGROUND: Available data on the clinical characteristics and prognosis of patients with heart failure (HF) due to dilated cardiomyopathy (DCM) derive mainly from tertiary care centres for cardiomyopathies or from drug trial sub-studies, which may entail a referral bias. METHODS: From 2008 to 2021, we enrolled in a nationwide HF Registry 1886 DCM patients and 3899 with ischemic heart disease (IHD). RESULTS: Patients with DCM were younger, more often female, had more commonly recent onset HF, left bundle branch block, and showed higher LV end-diastolic volume and lower LVEF than IHD...
March 19, 2024: International Journal of Cardiology
#8
JOURNAL ARTICLE
Anette Schrag, Karel Kostev
PURPOSE: To examine the association of several antihypertensive medication classes with incidence of Parkinson's disease (PD), taking into account possible underlying conditions. METHODS: In a case-control study based on a large primary care database and including 21,981 PD cases and 21,981 non-PD controls matched for age, sex, and possible treatment indications associations with different antihypertensive medication groups, including diuretics, betablockers, calcium channel blockers, angiotensin-converting enzyme inhibitors and angiotensin-II receptor-blockers and PD were examined...
2024: PloS One
#9
JOURNAL ARTICLE
Mustafa Korkmaz, Melek Karakurt Eryılmaz, Mehmet Zahid Koçak, Muhammed Muhiddin Er, Engin Hendem, Aykut Demirkıran, Murat Araz, Mehmet Artaç
PURPOSE: Vascular endothelial growth factor (VEGF) inhibition is one of the cornerstones of treatment in the treatment of metastatic renal cell carcinoma (mRCC). Since RCC is a disease of advanced age and hypertension as a side effect of VEGF receptor inhibitors, beta-blocker use is common in these patients. We aimed to compare the treatment efficacy and survival results in case of concomitant use of these two drugs due to the inhibition of VEGF in beta-blockers. METHODS: A total of 121 patients with a diagnosis of mRCC who used sunitinib or pazopanib in first-line therapy were included in the study...
March 13, 2024: European Journal of Clinical Pharmacology
#10
JOURNAL ARTICLE
Management and outcome in foreign-born vs native-born patients with myocardial infarction in Sweden.
Sammy Zwackman, Jenny Häggström, Emil Hagström, Tomas Jernberg, Jan-Erik Karlsson, Sofia Sederholm Lawesson, Margret Leosdottir, Annica Ravn-Fischer, Marie Eriksson, Joakim Alfredsson
BACKGROUND: Previous studies on disparities in healthcare and outcome have shown conflicting results. The aim of this study was to assess differences in baseline characteristics, management, and outcome in myocardial infarction (MI) patients, by country of birth. METHODS: In total, 194 259 MI patients (64% male, 15% foreign-born) from the nationwide SWEDEHEART registry were included and compared by geographic region of birth. The primary outcome was one-year major adverse cardiovascular events (MACE) including all-cause death, MI, and stroke...
March 7, 2024: European Heart Journal. Quality of Care & Clinical Outcomes
#11
JOURNAL ARTICLE
Naïbé Dangwé Temoua, Joel Bamouni, Dakaboué Germain Mandi, Elisé Kaboré, Lucien Allawaye, Mianroh Hybi Langtar, Allamine Adjougoulta, Narcisse Douné, Ali Adam, Abdelmadjeib Zakaria, Yaméogo Rélwendé Aristide, Kambiré Yibar, Koudougou Jonas Kologo, Georges Rosario Christian Millogo, Nobila Valentin Yaméogo, Patrice Zabsonré
Peripartum cardiomyopathy (PPCM) is a rare and potentially life-threatening disease associated with pregnancy. There are limited data regarding the outcome of PPCM and its predictive factors in sub-Saharan African patients. We prospectively conducted a double-center (cardiology unit of the department of medicine, Regional Hospital Center of Tenkodogo, Burkina Faso and the department of cardiology of the National Referral Teaching Hospital of N´Djamena, Chad) cohort study in patients with PPCM. Patients were consecutively enrolled from January 2015 to December 2017...
2024: Pan African Medical Journal
#12
JOURNAL ARTICLE
Milind Y Desai, Adel Hajj-Ali, Katy Rutkowski, Susan Ospina, Andrew Gaballa, Michael Emery, Craig Asher, Bo Xu, Maran Thamilarasan, Zoran B Popovic
BACKGROUND: In symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients, mavacamten is commercially approved to help improve left ventricular (LV) outflow tract (LVOT) gradients, symptoms, and reduce eligibility for septal reduction therapy (SRT) under the risk evaluation and mitigation strategy (REMS) program. We sought to prospectively report the initial real-world clinical experience with the use of commercially available mavacamten in a multi-hospital tertiary healthcare system...
February 12, 2024: Progress in Cardiovascular Diseases
#13
REVIEW
Alberto Palazzuoli, Gaetano Ruocco, Marco Giuseppe Del Buono, Simona Pavoncelli, Elvira Delcuratolo, Antonio Abbate, Carl J Lavie
In the last decades, several classifications and definitions have been proposed for advanced heart failure (ADVHF) patients, including clinical, functional, hemodynamic, imaging, and electrocardiographic features. Despite different inclusion criteria, ADVHF is characterized by some common items, such as drug intolerance, low arterial pressure, multiple organ dysfunction, chronic kidney disease, and diuretic use dependency. Additional features include fatigue, hypotension, hyponatremia, and unintentional weight loss associated with a specific laboratory profile reflecting systemic multiorgan dysfunction...
January 29, 2024: Heart Failure Reviews
#14
JOURNAL ARTICLE
Nanna Hansen, Annette Dam Fialla
INTRODUCTION: Portal pressure predicts the occurrence of decompensations in cirrhosis. Portal pressure is primarily measured via hepatic vein catheterisation (HVC), to which a transjugular liver biopsy (TJLB) may be added. Indications for HVC are mainly therapy control and prognosis. TJLB is performed when a percutaneous liver biopsy is contraindicated or for other diagnostic reasons. Both procedures have reported low complication rates. The aim of this study was to identify indications and 30-day postprocedural complications...
December 18, 2023: Danish Medical Journal
#15
JOURNAL ARTICLE
Mathias Jachs, Lukas Hartl, Benedikt Simbrunner, Georg Semmler, Lorenz Balcar, Benedikt Silvester Hofer, Michael Schwarz, David Bauer, Albert F Stättermayer, Matthias Pinter, Michael Trauner, Thomas Reiberger, Mattias Mandorfer
BACKGROUND AND AIMS: Non-invasive tests (NIT) for assessing the probability of clinically significant portal hypertension (CSPH) including the ANTICIPATE±NASH models based on liver stiffness measurement (LSM), platelet count (PLT)±body mass index (BMI), and the von Willebrand factor antigen (VWF) to PLT ratio (VITRO) have fundamentally changed the management of compensated advanced chronic liver disease (cACLD). However, their prognostic utility has not been compared head-to-head against the hepatic venous pressure gradient (HVPG) as the gold standard...
January 11, 2024: Journal of Hepatology
#16
JOURNAL ARTICLE
Matthias Peter Hilty, Christoph Siebenmann, Peter Rasmussen, Stefanie Keiser, Andrea Müller, Carsten Lundby, Marco Maggiorini
BACKGROUND: An increasing number of hypertensive persons travel to high altitude while using antihypertensive medications such as betablockers. Nevertheless, while hypoxic exposure initiates an increase in pulmonary artery pressure (Ppa) and pulmonary vascular resistance (PVR), the contribution of the autonomic nervous system is unclear. In animals, β-adrenergic blockade has induced pulmonary vasoconstriction in normoxia and exaggerated hypoxic pulmonary vasoconstriction (HPV) and both effects were abolished by muscarinic blockade...
January 12, 2024: European Heart Journal. Cardiovascular Pharmacotherapy
#17
JOURNAL ARTICLE
Laura Sofia Cardelli, Miloud Cherbi, Fabien Huet, Guillaume Schurtz, Eric Bonnefoy-Cudraz, Edouard Gerbaud, Laurent Bonello, Guillaume Leurent, Etienne Puymirat, Gianni Casella, Clément Delmas, François Roubille
BACKGROUND: Beta blockers (BBs) are a cornerstone for patients with heart failure (HF) and ventricular dysfunction. However, their use in patients recovering from a cardiogenic shock (CS) remains a bone of contention, especially regarding whether and when to reintroduce this class of drugs. METHODS: FRENSHOCK is a prospective multicenter registry including 772 CS patients from 49 centers. Our aim was to compare outcomes (1-month and 1-year all-cause mortality) between CS patients taking and those not taking BBs in three scenarios: (1) at 24 h after CS; (2) patients who did or did not discontinue BBs within 24 h; and (3) patients who did or did not undergo the early introduction of BBs...
December 18, 2023: Pharmaceuticals
#18
JOURNAL ARTICLE
John Munkhaugen, Elise Sverre, Toril Dammen, Einar Husebye, Erik Gjertsen, Oscar Kristiansen, Erlend Aune
BACKGROUND: There is limited knowledge from Norway on clinical characteristics, self-care and health literacy in patients admitted to hospital with acute heart failure. Our aim was to identify these factors in this group. MATERIAL AND METHOD: We included patients admitted with acute heart failure over a period of six months (2022/2023) at Drammen Hospital and Vestfold Hospital Trust. Cardiac nurses collected information from the patients, including self-assessed knowledge on an ordinal scale from 0 (little knowledge) to 10 (good knowledge)...
November 21, 2023: Tidsskrift for Den Norske Lægeforening: Tidsskrift for Praktisk Medicin, Ny Række
#19
JOURNAL ARTICLE
Celia Castaño-Amores, Alba Antúnez-Rodríguez, Ana Pozo-Agundo, Sonia García-Rodríguez, Luis Javier Martínez-González, Cristina Lucía Dávila-Fajardo
Betablockers (BBs) are prescribed for ischaemia in patients with acute coronary syndrome (ACS). In Spain, bisoprolol and carvedilol are the most prescribed BBs, but patients often had to discontinue them due to adverse effects. Single nucleotide polymorphisms (SNPs) in ADRB1, ADRB2 and CYP2D6 genes have strong evidence of pharmacogenetic association with BBs in heart failure or hypertension, but the evidence in ACS is limited. Therefore, our study focuses on investigating how these genes influence the response to BBs in ACS patients...
November 10, 2023: Biomedicine & Pharmacotherapy
#20
JOURNAL ARTICLE
Lorenz Balcar, Mattias Mandorfer, Virginia Hernández-Gea, Bogdan Procopet, Elias Laurin Meyer, Álvaro Giráldez, Lucio Amitrano, Candid Villanueva, Dominique Thabut, Luis Ibáñez Samaniego, Gilberto Silva-Junior, Javier Martinez, Joan Genescà, Christophe Bureau, Jonel Trebicka, Elba Llop Herrera, Wim Laleman, José María Palazón Azorín, Jose Castellote Alonso, Lise Lotte Gluud, Carlos Noronha Ferreira, Nuria Cañete, Manuel Rodríguez, Arnulf Ferlitsch, Jose Luis Mundi, Henning Grønbæk, Manuel Nicolas Hernandez Guerra, Romano Sassatelli, Alessandra Dell'Era, Marco Senzolo, Juan Gonzalez Abraldes, Manuel Romero-Gómez, Alexander Zipprich, Meritxell Casas, Helena Masnou, Massimo Primignani, Aleksander Krag, Frederik Nevens, Jose Luis Calleja, Christian Jansen, María Vega Catalina, Agustín Albillos, Marika Rudler, Edilmar Alvarado Tapias, Maria Anna Guardascione, Marcel Tantau, Rémy Schwarzer, Thomas Reiberger, Stig Borbjerg Laursen, Marta Lopez-Gomez, Alba Cachero, Alberto Ferrarese, Cristina Ripoll, Vincenzo La Mura, Jaime Bosch, Juan Carlos García-Pagán
BACKGROUND & AIMS: Pre-emptive transjugular intrahepatic portosystemic shunt (TIPS) is the treatment of choice for high-risk acute variceal bleeding (AVB; i.e., Child-Turcotte-Pugh [CTP] B8-9+active bleeding/C10-13). Nevertheless, some 'non-high-risk' patients have poor outcomes despite the combination of non-selective beta-blockers and endoscopic variceal ligation for secondary prophylaxis. We investigated prognostic factors for re-bleeding and mortality in 'non-high-risk' AVB to identify subgroups who may benefit from more potent treatments (i...
January 2024: Journal of Hepatology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
